anamorelin Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Anamorelin (INN), also known as anamorelin hydrochloride, is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is under development by Helsinn Healthcare SA for the treatment of cancer cachexia and anorexia.   Wikipedia

Chemistry

  • SMILES: CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1
  • InChIKey: VQPFSIRUEPQQPP-MXBOTTGLSA-N
  • Mol. Mass: 546.72
  • ALogP: 2.72
  • ChEMBL Molecules:
    anamorelin  
    anamorelin hydrochloride  
More Chemistry

Pharmacology

Alternative names

anamorelin | anamorelin hcl | anamorelin hydrochloride | ono-7643 | rc-1291 | rc-1291 hcl

Organizations (9)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Anorexia (Phase 2/Phase 3)

Bone Diseases, Metabolic (Phase 1)

Cachexia (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

C-Reactive Protein (Phase 2)

Lung Neoplasms (Phase 2/Phase 3)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Sarcopenia (Phase 1)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue